quinolinic acid has been researched along with Disease Models, Animal in 235 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kynurenine pathway, a neuroimmunological pathway plays a substantial role in depression." | 8.12 | Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies. ( Bansal, Y; Bishnoi, M; Dhingra, N; Dhingra, R; Khare, P; Kondepudi, KK; Kuhad, A; Singh, R; Sodhi, RK, 2022) |
| "Serotonin, a neurotransmitter synthesized from tryptophan, has been proposed to play a key role in central fatigue." | 7.78 | Essential role of excessive tryptophan and its neurometabolites in fatigue. ( Azechi, H; Board, M; Yamamoto, T, 2012) |
| " In this study, we investigated whether atorvastatin would have protective effects against hippocampal cell death promoted by quinolinic acid (QA)-induced seizures in mice." | 7.75 | Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. ( Boeck, CR; Carqueja, CL; Dal'agnolo, D; de Araújo Herculano, B; Martins, WC; Piermartiri, TC; Stroeh, E; Tasca, CI; Vandresen-Filho, S, 2009) |
| " In order to test this hypothesis, evaluation of glutathione (GSH) scavenger system was carried out in mice showing the neuroprotective effect of NMDA preconditioning against quinolinic acid (QA)-induced seizures." | 7.74 | Evaluation of glutathione metabolism in NMDA preconditioning against quinolinic acid-induced seizures in mice cerebral cortex and hippocampus. ( Boeck, CR; Dafre, AL; de Araújo Herculano, B; Franco, JL; Tasca, CI; Vandresen-Filho, S, 2007) |
| "Cryptotanshinone (CTS), a major constituent from the roots of Salvia miltiorrhiza (Danshen), is widely used in the treatment of coronary heart disease, stroke and less commonly Alzheimer's disease." | 7.74 | Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. ( Cao, J; Chan, E; Chen, X; Chowbay, B; Duan, W; Li, CG; Liang, J; Lin, SG; Wen, JY; Yu, XY; Zhou, SF; Zhou, ZW, 2007) |
| " Striatal injection of quinolinic acid (QUIN) resulted in marked inflammation characterized by microgliosis, astrogliosis and enhanced expressions of pro-inflammatory enzymes inducible nitric oxide synthase and cyclooxygenase-2." | 7.73 | Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. ( Choi, HB; McLarnon, JG; Ryu, JK, 2006) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 7.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| "Increased brain quinolinic acid (QUIN) levels have been suggested to play a role in hepatic encephalopathy (HE)." | 7.69 | Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: acute effects of L-tryptophan. ( Apelqvist, G; Bengtsson, F; Bergqvist, PB; Butterworth, RF; Heyes, MP, 1996) |
| "The eosinophilia-myalgia syndrome (EMS) is a recently described disease that has been associated with the ingestion of L-tryptophan containing trace amounts of several impurities." | 7.69 | A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan). ( Bingel, SA; Hampton, M; Harley, RA; Heyes, MP; Ludwicka, A; Maize, J; Ohba, T; Silver, RM; Smith, T, 1994) |
| "The pathomechanism of Alzheimer's disease (AD) certainly involves mitochondrial disturbances, glutamate excitotoxicity, and neuroinflammation." | 6.58 | Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. ( Klivényi, P; Szalárdy, L; Vécsei, L; Veres, G; Zádori, D, 2018) |
| " The QUIN is involved in the development of several toxic cascades which leads to the neuronal degeneration processes." | 5.48 | Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis. ( Goli, D; S, M; T, P, 2018) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 5.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| "In conclusion, the erythropoiesis in chronic renal failure could be attributed to the influence of QA on EPO synthesis." | 5.32 | Contribution of quinolinic acid in the development of anemia in renal insufficiency. ( Buczko, W; Koda, M; Pawlak, D; Pawlak, S; Wolczynski, S, 2003) |
| "QUIN seizures showed particular sensitivity to carbamazepine (5 mg/kg) but were resistant to diphenylhydantoin unless a relatively high dose was used (100 mg/kg)." | 5.27 | Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. ( Samanin, R; Tullii, M; Vezzani, A; Wu, HQ, 1986) |
| "Kynurenine pathway, a neuroimmunological pathway plays a substantial role in depression." | 4.12 | Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies. ( Bansal, Y; Bishnoi, M; Dhingra, N; Dhingra, R; Khare, P; Kondepudi, KK; Kuhad, A; Singh, R; Sodhi, RK, 2022) |
| "Huntington Disease (HD), a predominant Neurodegenerative Disorder which might be induced by endogenous neurotoxin called Quinolinic Acid (QA), an N-methyl-D aspartate receptor (NMDAR) agonist, the bilaterally intrastriatal administration (200 nm/2 μL of saline) offers rise to the toxic events like neuronal death, neuroinflammation by inflicting excitotoxicity and oxidative stress in the striatum of male Wistar rats by exhibiting the behavioural changes which was accessed by rotarod, open field analysis." | 4.12 | 5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington's like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathol ( Purushothaman, B; Sumathi, T, 2022) |
| "We created an excitotoxic striatal lesion model of Huntington disease (HD) in sheep, using the N-methyl-d-aspartate receptor agonist, quinolinic acid (QA)." | 3.96 | Longitudinal Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging in Sheep (Ovis aries) With Quinolinic Acid Lesions of the Striatum: Time-Dependent Recovery of N-Acetylaspartate and Fractional Anisotropy. ( Finnie, JW; Hemsley, KM; Kuchel, TR; Morton, AJ; Neumann, D; O'Connell, AB; Perumal, SR; Sherwood, V, 2020) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| " Notably, the anti-parasitic drugs pyrimethamine and sulfadiazine, a standard treatment of toxoplasmosis, significantly reduced 3-HK and KYNA levels in the brain of infected mice when applied between 28 and 56 days post-infection." | 3.80 | Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. ( Fang, Q; Harris, TH; Horning, KJ; Hunter, CA; Notarangelo, FM; Schwarcz, R; Thomas, MA; Wilson, EH, 2014) |
| "Serotonin, a neurotransmitter synthesized from tryptophan, has been proposed to play a key role in central fatigue." | 3.78 | Essential role of excessive tryptophan and its neurometabolites in fatigue. ( Azechi, H; Board, M; Yamamoto, T, 2012) |
| " In this study, we investigated whether atorvastatin would have protective effects against hippocampal cell death promoted by quinolinic acid (QA)-induced seizures in mice." | 3.75 | Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. ( Boeck, CR; Carqueja, CL; Dal'agnolo, D; de Araújo Herculano, B; Martins, WC; Piermartiri, TC; Stroeh, E; Tasca, CI; Vandresen-Filho, S, 2009) |
| " In order to test this hypothesis, evaluation of glutathione (GSH) scavenger system was carried out in mice showing the neuroprotective effect of NMDA preconditioning against quinolinic acid (QA)-induced seizures." | 3.74 | Evaluation of glutathione metabolism in NMDA preconditioning against quinolinic acid-induced seizures in mice cerebral cortex and hippocampus. ( Boeck, CR; Dafre, AL; de Araújo Herculano, B; Franco, JL; Tasca, CI; Vandresen-Filho, S, 2007) |
| "Cryptotanshinone (CTS), a major constituent from the roots of Salvia miltiorrhiza (Danshen), is widely used in the treatment of coronary heart disease, stroke and less commonly Alzheimer's disease." | 3.74 | Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. ( Cao, J; Chan, E; Chen, X; Chowbay, B; Duan, W; Li, CG; Liang, J; Lin, SG; Wen, JY; Yu, XY; Zhou, SF; Zhou, ZW, 2007) |
| "The brain levels of the endogenous excitotoxin quinolinic acid (QUIN) and its bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK), are elevated in early stage Huntington disease (HD)." | 3.73 | Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. ( Bates, GP; Graham, RK; Guidetti, P; Hayden, MR; Leavitt, BR; MacDonald, ME; Schwarcz, R; Slow, EJ; Wheeler, VC; Woodman, B, 2006) |
| " Striatal injection of quinolinic acid (QUIN) resulted in marked inflammation characterized by microgliosis, astrogliosis and enhanced expressions of pro-inflammatory enzymes inducible nitric oxide synthase and cyclooxygenase-2." | 3.73 | Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. ( Choi, HB; McLarnon, JG; Ryu, JK, 2006) |
| "Intrastriatal injection of quinolinic acid (QA) provides an animal model of Huntington disease." | 3.71 | Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy. ( Gruetter, R; Keene, CD; Low, WC; Pfeuffer, J; Tkác, I, 2001) |
| "In the present experiment we studied the ability of embryonic striatal grafts to protect against striatal quinolinic acid (QA)-induced excitotoxicity in a previously established double lesion rat model of striatonigral degeneration (SND), the neuropathological substrate of parkinsonism associated with multiple system atrophy (MSA)." | 3.70 | Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). ( Humpel, C; Levivier, M; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Stefanova, N; Waldner, R; Wenning, GK, 2000) |
| "The eosinophilia-myalgia syndrome (EMS) is a recently described disease that has been associated with the ingestion of L-tryptophan containing trace amounts of several impurities." | 3.69 | A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan). ( Bingel, SA; Hampton, M; Harley, RA; Heyes, MP; Ludwicka, A; Maize, J; Ohba, T; Silver, RM; Smith, T, 1994) |
| " With the intent of producing a more reliable behavioral model of Huntington disease, anatomically-defined lesions of limited size were produced by magnetic resonance imaging-guided stereotaxic injection of quinolinic acid in specific regions within the caudate and putamen of rhesus monkeys." | 3.69 | Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. ( Brownell, AL; Burns, LH; Deacon, TW; Isacson, O; Jenkins, BG; Pakzaban, P; Tatter, SB, 1995) |
| "Using murine AIDS (MAIDS) as a model of retrovirus-induced immunodeficiency, the aims of this study were (1) to determine the cellular source(s) of quinolinic acid (Quin) with regard to its significance as a potential neuroexcitotoxin in AIDS dementia complex, and (2) to characterize the relationship between dendritic cell Quin immunoreactivity and the histopathological changes associated with the progression of disease." | 3.69 | Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis. ( Espey, MG; Moffett, JR; Morse, HC; Namboodiri, MA; Tang, Y, 1996) |
| "Increased brain quinolinic acid (QUIN) levels have been suggested to play a role in hepatic encephalopathy (HE)." | 3.69 | Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: acute effects of L-tryptophan. ( Apelqvist, G; Bengtsson, F; Bergqvist, PB; Butterworth, RF; Heyes, MP, 1996) |
| "The pathomechanism of Alzheimer's disease (AD) certainly involves mitochondrial disturbances, glutamate excitotoxicity, and neuroinflammation." | 2.58 | Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. ( Klivényi, P; Szalárdy, L; Vécsei, L; Veres, G; Zádori, D, 2018) |
| "The neurodegenerative disease Huntington's disease (HD) is caused by an expanded polyglutamine (polyQ) tract in the protein huntingtin (htt)." | 2.46 | Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. ( Guidetti, P; Muchowski, PJ; Sathyasaikumar, KV; Schwarcz, R, 2010) |
| "Spontaneous recurrent seizures induced by pilocarpine were monitored behaviorally prior to and after PING or under control conditions." | 1.62 | Non-invasive, neurotoxic surgery reduces seizures in a rat model of temporal lobe epilepsy. ( Bertram, EH; Buckmaster, PS; Ghobadi, SN; Habte, FG; Hou, Q; Huang, A; Keunen, O; Lee, KS; Li, N; Narang, S; Qiu, L; Wang, J; Wintermark, M; Zhang, Y, 2021) |
| "Quinolinic acid (QUIN) is an agonist of the neurotransmitter glutamate (Glu) capable of binding to N-methyl-D-aspartate receptors (NMDAR) increasing glutamatergic signaling." | 1.62 | Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders. ( Antunes Soares, FA; Aschner, M; Bicca Obetine Baptista, F; Duarte Hartmann, D; Farina Gonçalves, D; Franzen da Silva, A; Lenz Dalla Corte, C; Limana da Silveira, T; Lopes Machado, M; Marafiga Cordeiro, L, 2021) |
| " However, their toxic properties have yet to be explored in the nematode Caenorhabditis elegans (C." | 1.48 | Comparison of the Toxic Effects of Quinolinic Acid and 3-Nitropropionic Acid in C. elegans: Involvement of the SKN-1 Pathway. ( Aguilera-González, MF; Aschner, M; Avila, DS; Colonnello, A; de Lima, ME; García-Contreras, R; Kotlar, I; Ortíz-Plata, A; Santamaría, A; Soares, FAA, 2018) |
| " The QUIN is involved in the development of several toxic cascades which leads to the neuronal degeneration processes." | 1.48 | Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis. ( Goli, D; S, M; T, P, 2018) |
| "Ferulic acid (FA) is a phenolic compound possessing antioxidant and cytoprotective properties." | 1.48 | Comparing the Effects of Ferulic Acid and Sugarcane Aqueous Extract in In Vitro and In Vivo Neurotoxic Models. ( Aschner, M; Colonnello, A; de Lima, ME; García-Contreras, R; Kotlar, I; Ortíz-Plata, A; Santamaría, A; Soares, FAA, 2018) |
| " This abnormal proteolysis leads to the accumulation of cleaved fragments, which have been identified as toxic and further they act as a seed for more aggregate formation, thereby increasing toxicity in neuronal cells." | 1.46 | n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3. ( Chiang, IT; Chiou, TW; Harn, HJ; Hsieh, DK; Lin, SY; Lin, SZ; Liu, JW; Rajamani, K; Wu, CH; You, DH, 2017) |
| "Huntington Disease is autosomal, fatal and progressive neurodegenerative disorder for which clinically available drugs offer only symptomatic relief." | 1.46 | Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation. ( Deshmukh, R; Gill, JS; Jamwal, S; Kumar, P, 2017) |
| "Huntington disease is hyperkinetic movement disorder characterized by selective and immense degradation of GABAergic medium spiny neurons in striatum." | 1.42 | Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism. ( Jamwal, S; Kaur, N; Kumar, P; Singh, S, 2015) |
| "Standardized spinal cord injuries were produced in anesthetized guinea pigs, using lateral compression of the spinal cord." | 1.40 | Effects of methylprednisolone and 4-chloro-3-hydroxyanthranilic acid in experimental spinal cord injury in the guinea pig appear to be mediated by different and potentially complementary mechanisms. ( Blight, AR; Gay, EA; Heyes, MP; Yates, JR, 2014) |
| "Treatment with rosiglitazone (5, 10 mg/kg) and VPA (100, 200 mg/kg) for 21 days significantly attenuated these behavioral, biochemical, and cellular alterations as compared to control (QA 200 nmol) group." | 1.40 | Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways. ( Chaudhary, T; Kumar, A; Mishra, J, 2014) |
| "Melatonin was partially effective against the inhibition of striatal catalase activity and a decrease of non-protein thiol levels induced by quinolinic acid." | 1.39 | Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin. ( Antunes Wilhelm, E; Folharini Bortolatto, C; Ricardo Jesse, C; Wayne Nogueira, C, 2013) |
| " Our data suggest that the two studied toxic models (QA and 3-NP) or the combined model (QA plus 3-NP) can generate complex patterns of damage, which involve metabolic compromise, ROS formation, and oxidative stress." | 1.38 | Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. ( Colle, D; Farina, M; Hartwig, JM; Soares, FA, 2012) |
| "Because Huntington's disease mouse models develop resistance to excitotoxicity, we analyzed whether decreased STEP activity was involved in this process." | 1.37 | Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. ( Alberch, J; Giralt, A; Lombroso, PJ; Lucas, JJ; Ortega, Z; Pérez-Navarro, E; Rué, L; Saavedra, A; Xifró, X; Xu, J, 2011) |
| "Huntington disease is a neurodegenerative disease with complex pathophysiology." | 1.37 | Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. ( Kalonia, H; Kumar, A; Kumar, P, 2011) |
| " Moreover, the administration of MK-801 to rats as a pretreatment resulted in a complete prevention of the QUIN-induced NAD(P)H activation, suggesting that this toxic event is completely dependent on N-methyl-D-aspartate receptor overactivation." | 1.36 | NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin. ( Galván-Arzate, S; Maldonado, PD; Molina-Jijón, E; Pedraza-Chaverrí, J; Santamaría, A; Villeda-Hernández, J, 2010) |
| "Quinolinic acid (QUIN) was used as a typical excitotoxic/pro-oxidant inducer, 3-nitropropionic acid (3-NP) was employed as a mitochondrial function inhibitor, and their combination (QUIN + 3-NP) was also evaluated in in vitro studies." | 1.36 | Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine. ( Elinos-Calderón, D; Galván-Arzate, S; Maldonado, PD; Pedraza-Chaverrí, J; Pérez-De La Cruz, V; Robledo-Arratia, Y; Santamaría, A, 2010) |
| "QA is used in experimental models of seizures studying the effects of overstimulation of the glutamatergic system." | 1.36 | Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model. ( Antoniolli, E; Antunes, C; da Silva Filho, M; Kalinine, E; Portela, LV; Souza, DO; Torres, FV; Tort, AB, 2010) |
| "Quinolinic acid has been reported to induce excitotoxicity by stimulating the N-methyl-D-aspartate receptor, causing calcium overload which in turn leads to the neurodegeneration." | 1.36 | Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2010) |
| "Thus, nociceptive and neuropathic pain belongs--in addition to behavioral changes--among the parameters which are affected in described animal models of schizophrenia." | 1.36 | Pain perception in neurodevelopmental animal models of schizophrenia. ( Bubeníková-Valešová, V; Franěk, M; Rokyta, R; Šťastný, F; Vaculín, S; Yamamotová, A, 2010) |
| "Huntington's disease is an inherited neurodegenerative disorder, characterized by loss of spiny neurons in the striatum and cortex, which usually happens in the third or fourth decades of life." | 1.35 | Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration. ( Ali, M; Amin, EM; Maryam, MM; Morteza, BR; Reza, BA; Zeinab, N, 2008) |
| "Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors." | 1.35 | Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2009) |
| "These changes preceded the onset of EEG seizures, which had a mean onset of 108 h after inoculation." | 1.35 | Glial activation precedes seizures and hippocampal neurodegeneration in measles virus-infected mice. ( Bertram, EH; Guidetti, P; Lehrmann, E; Löve, A; Schwarcz, R; Williamson, J, 2008) |
| " The injection coordinates and the dosage of quinolinic acid were identical." | 1.35 | Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease. ( Büchele, F; Döbrössy, M; Jiang, W; Nikkhah, G; Papazoglou, A, 2009) |
| "Huntington's disease is an inherited neurodegenerative condition characterized by movement disorders, and mood and cognitive disturbance." | 1.33 | Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease. ( Barker, RA; Morton, AJ; Phillips, W, 2006) |
| "This relationship is altered in Parkinsonism and in levodopa-induced dyskinesias (LID), resulting in an upregulation of corticostriatal glutamatergic function." | 1.33 | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. ( Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R, 2005) |
| "However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated." | 1.33 | Minocycline in phenotypic models of Huntington's disease. ( Bantubungi, K; Blum, D; Brotchi, J; Brouillet, E; Chtarto, A; Déglon, N; Galas, MC; Greco, A; Jacquard, C; Levivier, M; Minghetti, L; Pintor, A; Popoli, P; Schiffmann, SN; Tai, K; Tenenbaum, L, 2005) |
| "Ten minutes of global cerebral ischemia did not modify the interaction between KAIN and KYNA." | 1.33 | Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs. ( Bari, F; Busija, DW; Domoki, F; Guidetti, P; Nagy, K; Schwarcz, R, 2006) |
| "Riluzole was administered prior to and consecutively for ten days following double lesion placement in the left-sided medial forebrain bundle and ipsilateral striatum." | 1.33 | Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). ( Diguet, E; Poewe, W; Puschban, Z; Sather, T; Scherfler, C; Stefanova, N; Tison, F; Wenning, GK, 2005) |
| " A lower pyruvate concentration of 250 mg/kg was not protective; however, quadruple applications at this dosage was effective in reducing lesion volumes." | 1.32 | Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease. ( Kim, SU; McLarnon, JG; Ryu, JK, 2003) |
| "Symptoms in the early stages of Huntington's disease (HD) are assumed to reflect basal ganglia circuit dysfunction secondary to degeneration of striatal projections to the external segment of the globus pallidus (GPe)." | 1.32 | Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease. ( Ayalon, L; Joel, D; Tarrasch, R; Weiner, I, 2003) |
| "Quinolinic acid (QA) has been used as a model for experimental overstimulation of the glutamatergic system." | 1.32 | Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine. ( de Oliveira, DL; Frizzo, ME; Horn, JF; Moriguchi, E; Rodrigues, JM; Souza, DO; Wofchuk, S, 2004) |
| "In conclusion, the erythropoiesis in chronic renal failure could be attributed to the influence of QA on EPO synthesis." | 1.32 | Contribution of quinolinic acid in the development of anemia in renal insufficiency. ( Buczko, W; Koda, M; Pawlak, D; Pawlak, S; Wolczynski, S, 2003) |
| " These results establish the proof of principle of neurotrophic factor dosing for neurodegenerative diseases and demonstrate the feasibility of lentiviral-mediated tetracycline-regulated gene transfer in the brain." | 1.31 | Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. ( Aebischer, P; Déglon, N; Pereira de Almeida, L; Régulier, E; Sommer, B, 2002) |
| "Striatal neurons in symptomatic Huntington's disease (HD) transgenic mice are resistant to a variety of toxic insults, including quinolinic acid (QA), kainic acid and 3-nitropropionic acid." | 1.31 | Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice. ( Costain, WJ; Crocker, SF; Denovan-Wright, EM; Hamilton, LC; MacGibbon, GA; Murphy, KM; Robertson, HA, 2002) |
| "Huntington's disease is a progressive, inherited neurodegenerative disorder characterized by the loss of subsets of neurons primarily in the striatum." | 1.31 | Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. ( Chuang, DM; Qian, Y; Qin, ZH; Senatorov, VV; Wang, Y; Wei, H; Wei, W, 2001) |
| "Quinolinic acid (QA) is an N-methyl-d-aspartate agonist that has been shown to produce neurotoxic effects that mimic certain neurodegenerative diseases when administered to laboratory animals." | 1.31 | Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease. ( Dunbar, GL; Haik, KL; Sabel, BA; Schroeder, U; Shear, DA, 2000) |
| "Huntington's disease is a progressive neurodegenerative disease characterized by movement disorder, cognitive deterioration, and selective striatal degeneration." | 1.31 | Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. ( Emborg, ME; Kordower, JH; Palfi, S; Roitberg, BZ; Sramek, JG, 2002) |
| "A transgenic mouse model of Huntington's disease (R6/1 and R6/2 lines) expressing exon 1 of the HD gene with 115-150 CAG repeats resisted striatal damage following injection of quinolinic acid and other neurotoxins." | 1.31 | Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. ( Aronin, N; Brundin, P; Chase, K; DiFiglia, M; Petersén, A; Puschban, Z, 2002) |
| "Huntington's disease is a genetic disorder that results from degeneration of striatal neurons, particularly those containing GABA (gamma-aminobutyric acid)." | 1.30 | Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. ( Baetge, EE; Chen, EY; Chu, Y; Emerich, DF; Hantraye, PM; Kordower, JH; McDermott, P; Peschanski, M; Winn, SR, 1997) |
| "Huntington's disease is an incurable genetic neurological disorder characterized by the relatively selective degeneration of the striatum." | 1.30 | The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. ( Alexi, T; Clark, RG; Faull, RL; Gluckman, PD; Hughes, PE; van Roon-Mom, WM; Williams, CE, 1999) |
| "Quinolinic acid (QUIN) is an endogenous neurotoxic N-methyl-D-aspartate agonist that may contribute to the pathogenesis of HIV-associated neurologic disease." | 1.29 | Quinolinic acid levels in a murine retrovirus-induced immunodeficiency syndrome. ( Hartley, JW; Heyes, MP; Layar, R; Morse, HC; Paul, IA; Saito, K; Sei, Y; Skolnick, P, 1996) |
| "Huntington disease is a dominantly inherited, untreatable neurological disorder featuring a progressive loss of striatal output neurons that results in dyskinesia, cognitive decline, and, ultimately, death." | 1.29 | Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. ( Anderson, KD; Corcoran, TL; Lindsay, RM; Panayotatos, N; Wiegand, SJ, 1996) |
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| "QUIN seizures showed particular sensitivity to carbamazepine (5 mg/kg) but were resistant to diphenylhydantoin unless a relatively high dose was used (100 mg/kg)." | 1.27 | Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. ( Samanin, R; Tullii, M; Vezzani, A; Wu, HQ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (2.98) | 18.7374 |
| 1990's | 46 (19.57) | 18.2507 |
| 2000's | 93 (39.57) | 29.6817 |
| 2010's | 77 (32.77) | 24.3611 |
| 2020's | 12 (5.11) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, T | 1 |
| Mo, JH | 1 |
| Gong, X | 1 |
| Rossetto, C | 1 |
| Jang, A | 1 |
| Beck, L | 1 |
| Elliott, GI | 1 |
| Kufareva, I | 1 |
| Abagyan, R | 1 |
| Broide, DH | 1 |
| Lee, J | 1 |
| Raz, E | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Martínez-Gopar, PE | 2 |
| Pérez-Rodríguez, MJ | 1 |
| Rodríguez-Manzo, G | 1 |
| Garduño-Gutierrez, R | 1 |
| Tristán-López, L | 2 |
| Angeles-López, QD | 1 |
| González-Espinosa, C | 1 |
| Pérez-Severiano, F | 5 |
| Barbieri Caus, L | 1 |
| Pasquetti, MV | 1 |
| Seminotti, B | 3 |
| Woontner, M | 1 |
| Wajner, M | 3 |
| Calcagnotto, ME | 1 |
| Bansal, Y | 2 |
| Singh, R | 2 |
| Sodhi, RK | 2 |
| Khare, P | 1 |
| Dhingra, R | 1 |
| Dhingra, N | 1 |
| Bishnoi, M | 2 |
| Kondepudi, KK | 1 |
| Kuhad, A | 2 |
| Yedke, NG | 1 |
| Arthur, R | 1 |
| Kumar, P | 8 |
| Yoon, Y | 1 |
| Kim, HS | 1 |
| Jeon, I | 1 |
| Noh, JE | 1 |
| Park, HJ | 1 |
| Lee, S | 1 |
| Park, IH | 1 |
| Stevanato, L | 1 |
| Hicks, C | 1 |
| Corteling, R | 1 |
| Barker, RA | 3 |
| Sinden, JD | 1 |
| Song, J | 1 |
| O'Connell, AB | 1 |
| Kuchel, TR | 1 |
| Perumal, SR | 1 |
| Sherwood, V | 1 |
| Neumann, D | 1 |
| Finnie, JW | 1 |
| Hemsley, KM | 1 |
| Morton, AJ | 2 |
| Stepanova, P | 1 |
| Srinivasan, V | 1 |
| Lindholm, D | 1 |
| Voutilainen, MH | 1 |
| Saroj, P | 1 |
| Akhtar, A | 1 |
| Sah, SP | 1 |
| Zhang, Y | 2 |
| Buckmaster, PS | 2 |
| Qiu, L | 1 |
| Wang, J | 3 |
| Keunen, O | 1 |
| Ghobadi, SN | 1 |
| Huang, A | 1 |
| Hou, Q | 1 |
| Li, N | 1 |
| Narang, S | 1 |
| Habte, FG | 2 |
| Bertram, EH | 3 |
| Lee, KS | 2 |
| Wintermark, M | 2 |
| Limana da Silveira, T | 1 |
| Lopes Machado, M | 1 |
| Bicca Obetine Baptista, F | 1 |
| Farina Gonçalves, D | 1 |
| Duarte Hartmann, D | 1 |
| Marafiga Cordeiro, L | 1 |
| Franzen da Silva, A | 1 |
| Lenz Dalla Corte, C | 1 |
| Aschner, M | 3 |
| Antunes Soares, FA | 1 |
| Purushothaman, B | 1 |
| Sumathi, T | 1 |
| Formisano, S | 1 |
| Hornig, M | 1 |
| Yaddanapudi, K | 1 |
| Vasishtha, M | 1 |
| Parsons, LH | 1 |
| Briese, T | 1 |
| Lipkin, WI | 1 |
| Williams, BL | 1 |
| Pierozan, P | 1 |
| Pessoa-Pureur, R | 1 |
| Parasram, K | 1 |
| Kotlar, I | 2 |
| Colonnello, A | 2 |
| Aguilera-González, MF | 1 |
| Avila, DS | 1 |
| de Lima, ME | 2 |
| García-Contreras, R | 2 |
| Ortíz-Plata, A | 2 |
| Soares, FAA | 2 |
| Santamaría, A | 11 |
| Li, X | 1 |
| He, S | 1 |
| Hu, L | 1 |
| Guo, J | 1 |
| Huang, X | 1 |
| Hu, J | 1 |
| Qi, Y | 1 |
| Chen, B | 1 |
| Shang, D | 1 |
| Wen, Y | 1 |
| Amaral, AU | 1 |
| da Silva, JC | 1 |
| de Oliveira, FH | 1 |
| Ribeiro, RT | 1 |
| Vargas, CR | 1 |
| Leipnitz, G | 2 |
| Souza, DO | 5 |
| Zádori, D | 1 |
| Veres, G | 1 |
| Szalárdy, L | 1 |
| Klivényi, P | 1 |
| Vécsei, L | 1 |
| Harrison, DJ | 1 |
| Roberton, VH | 1 |
| Vinh, NN | 1 |
| Brooks, SP | 1 |
| Dunnett, SB | 10 |
| Rosser, AE | 2 |
| Lelos, MJ | 1 |
| Elmer, GI | 1 |
| Palacorolla, H | 1 |
| Mayo, CL | 1 |
| Brown, PL | 1 |
| Jhou, TC | 1 |
| Brady, D | 1 |
| Shepard, PD | 1 |
| S, M | 1 |
| T, P | 1 |
| Goli, D | 1 |
| Rahman, A | 1 |
| Rao, MS | 1 |
| Khan, KM | 1 |
| Liao, C | 1 |
| Qu, H | 1 |
| Huang, S | 1 |
| Jiang, H | 1 |
| Zhou, H | 1 |
| Abrams, E | 1 |
| Yuan, L | 1 |
| Pauly, KB | 1 |
| Lavisse, S | 1 |
| Williams, S | 1 |
| Lecourtois, S | 1 |
| van Camp, N | 1 |
| Guillermier, M | 1 |
| Gipchtein, P | 1 |
| Jan, C | 1 |
| Goutal, S | 1 |
| Eymin, L | 1 |
| Valette, J | 1 |
| Delzescaux, T | 1 |
| Perrier, AL | 1 |
| Hantraye, P | 1 |
| Aron Badin, R | 1 |
| Kaindlstorfer, C | 2 |
| Stefanova, N | 7 |
| Garcia, J | 2 |
| Krismer, F | 1 |
| Döbrössy, M | 2 |
| Göbel, G | 1 |
| Jellinger, K | 2 |
| Granata, R | 1 |
| Wenning, GK | 9 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 1 |
| Chrétien, F | 1 |
| Gaillard, R | 1 |
| Liu, P | 1 |
| Li, Y | 1 |
| Qi, X | 1 |
| Xu, J | 2 |
| Liu, D | 1 |
| Ji, X | 1 |
| Chi, T | 1 |
| Liu, H | 1 |
| Zou, L | 1 |
| Tronel, C | 1 |
| Rochefort, GY | 1 |
| Arlicot, N | 1 |
| Bodard, S | 1 |
| Chalon, S | 1 |
| Antier, D | 1 |
| Lindgren, HS | 1 |
| Wickens, R | 1 |
| Tait, DS | 1 |
| Brown, VJ | 1 |
| Strong, MK | 1 |
| Southwell, AL | 1 |
| Yonan, JM | 1 |
| Hayden, MR | 3 |
| Macgregor, GR | 1 |
| Thompson, LM | 2 |
| Steward, O | 2 |
| Retailleau, A | 1 |
| Dejean, C | 1 |
| Fourneaux, B | 1 |
| Leinekugel, X | 1 |
| Boraud, T | 1 |
| Schackel, S | 1 |
| Pauly, MC | 1 |
| Piroth, T | 1 |
| Nikkhah, G | 3 |
| Döbrössy, MD | 5 |
| Daschil, N | 1 |
| Obermair, GJ | 1 |
| Flucher, BE | 1 |
| Hutter-Paier, B | 1 |
| Windisch, M | 1 |
| Humpel, C | 2 |
| Marksteiner, J | 1 |
| Mazarei, G | 1 |
| Budac, DP | 2 |
| Lu, G | 2 |
| Lee, H | 1 |
| Möller, T | 1 |
| Leavitt, BR | 3 |
| Kumar, A | 8 |
| Chaudhary, T | 2 |
| Mishra, J | 3 |
| Vallerini, GP | 1 |
| Amori, L | 1 |
| Beato, C | 1 |
| Tararina, M | 1 |
| Wang, XD | 1 |
| Schwarcz, R | 9 |
| Costantino, G | 1 |
| Notarangelo, FM | 1 |
| Wilson, EH | 1 |
| Horning, KJ | 1 |
| Thomas, MA | 1 |
| Harris, TH | 1 |
| Fang, Q | 1 |
| Hunter, CA | 1 |
| Tremblay, M | 1 |
| Cocker, PJ | 1 |
| Hosking, JG | 1 |
| Zeeb, FD | 1 |
| Rogers, RD | 1 |
| Winstanley, CA | 1 |
| Zavitsanou, K | 1 |
| Lim, CK | 1 |
| Purves-Tyson, T | 1 |
| Karl, T | 1 |
| Kassiou, M | 1 |
| Banister, SD | 1 |
| Guillemin, GJ | 1 |
| Weickert, CS | 1 |
| Yates, JR | 1 |
| Gay, EA | 1 |
| Heyes, MP | 10 |
| Blight, AR | 2 |
| Mu, S | 1 |
| Zhou, G | 1 |
| Peng, W | 1 |
| He, Z | 1 |
| Zhao, Z | 1 |
| Mo, C | 1 |
| Qu, J | 1 |
| Zhang, J | 1 |
| Martínez-Lazcano, JC | 2 |
| Montes, S | 2 |
| Sánchez-Mendoza, MA | 1 |
| Rodríguez-Páez, L | 1 |
| Pérez-Neri, I | 2 |
| Boll, MC | 1 |
| Campos-Arroyo, HD | 1 |
| Ríos, C | 2 |
| Yoon, HH | 1 |
| Kim, YH | 1 |
| Shin, ES | 1 |
| Jeon, SR | 1 |
| Giorgetto, C | 1 |
| Silva, EC | 1 |
| Kitabatake, TT | 1 |
| Bertolino, G | 1 |
| de Araujo, JE | 1 |
| García-Lara, L | 1 |
| González-Esquivel, D | 1 |
| Elizondo, G | 1 |
| Segovia, J | 1 |
| Jamwal, S | 2 |
| Singh, S | 1 |
| Kaur, N | 1 |
| Colín-González, AL | 1 |
| Paz-Loyola, AL | 1 |
| Serratos, I | 1 |
| Ribeiro, CA | 1 |
| Shibata, K | 2 |
| Kuzdas-Wood, D | 1 |
| Fellner, L | 1 |
| Premstaller, M | 1 |
| Borm, C | 1 |
| Bloem, B | 1 |
| Kirik, D | 1 |
| Morales-Martínez, A | 1 |
| Sánchez-Mendoza, A | 1 |
| Pineda-Farías, JB | 1 |
| El-Hafidi, M | 1 |
| Zamorano-Carrillo, A | 1 |
| Castro, N | 1 |
| Beaumont, V | 1 |
| Mrzljak, L | 1 |
| Dijkman, U | 1 |
| Freije, R | 1 |
| Heins, M | 1 |
| Rassoulpour, A | 3 |
| Tombaugh, G | 1 |
| Gelman, S | 1 |
| Bradaia, A | 1 |
| Steidl, E | 1 |
| Gleyzes, M | 1 |
| Heikkinen, T | 1 |
| Lehtimäki, K | 1 |
| Puoliväli, J | 1 |
| Kontkanen, O | 1 |
| Javier, RM | 1 |
| Neagoe, I | 1 |
| Deisemann, H | 1 |
| Winkler, D | 1 |
| Ebneth, A | 1 |
| Khetarpal, V | 1 |
| Toledo-Sherman, L | 1 |
| Dominguez, C | 1 |
| Park, LC | 1 |
| Munoz-Sanjuan, I | 1 |
| Eskelund, A | 1 |
| Sanchez, C | 1 |
| Elfving, B | 1 |
| Wegener, G | 1 |
| Tartaglione, AM | 1 |
| Armida, M | 1 |
| Potenza, RL | 2 |
| Pezzola, A | 8 |
| Popoli, P | 9 |
| Calamandrei, G | 3 |
| Saliba, SW | 1 |
| Vieira, EL | 1 |
| Santos, RP | 1 |
| Candelario-Jalil, E | 1 |
| Fiebich, BL | 1 |
| Vieira, LB | 1 |
| Teixeira, AL | 1 |
| de Oliveira, AC | 1 |
| Gill, JS | 1 |
| Deshmukh, R | 1 |
| Rajamani, K | 1 |
| Liu, JW | 1 |
| Wu, CH | 1 |
| Chiang, IT | 1 |
| You, DH | 1 |
| Lin, SY | 1 |
| Hsieh, DK | 1 |
| Lin, SZ | 1 |
| Harn, HJ | 1 |
| Chiou, TW | 1 |
| Karl, JM | 1 |
| Sacrey, LA | 1 |
| McDonald, RJ | 1 |
| Whishaw, IQ | 1 |
| Amin, EM | 1 |
| Reza, BA | 1 |
| Morteza, BR | 1 |
| Maryam, MM | 1 |
| Ali, M | 1 |
| Zeinab, N | 1 |
| Pérez-De La Cruz, V | 5 |
| Elinos-Calderón, D | 3 |
| Robledo-Arratia, Y | 3 |
| Medina-Campos, ON | 1 |
| Pedraza-Chaverrí, J | 5 |
| Ali, SF | 3 |
| Graham, RK | 2 |
| Pouladi, MA | 1 |
| Joshi, P | 1 |
| Deng, Y | 1 |
| Wu, NP | 1 |
| Figueroa, BE | 1 |
| Metzler, M | 1 |
| André, VM | 2 |
| Slow, EJ | 2 |
| Raymond, L | 1 |
| Friedlander, R | 1 |
| Levine, MS | 2 |
| Giampà, C | 5 |
| Patassini, S | 3 |
| Borreca, A | 1 |
| Laurenti, D | 1 |
| Marullo, F | 1 |
| Bernardi, G | 5 |
| Menniti, FS | 1 |
| Fusco, FR | 6 |
| Guidetti, P | 6 |
| Sathyasaikumar, KV | 1 |
| Muchowski, PJ | 1 |
| Jiang, W | 1 |
| Büchele, F | 1 |
| Papazoglou, A | 1 |
| Piermartiri, TC | 1 |
| Vandresen-Filho, S | 2 |
| de Araújo Herculano, B | 2 |
| Martins, WC | 1 |
| Dal'agnolo, D | 1 |
| Stroeh, E | 1 |
| Carqueja, CL | 1 |
| Boeck, CR | 3 |
| Tasca, CI | 2 |
| Emerich, DF | 4 |
| Mooney, DJ | 1 |
| Storrie, H | 1 |
| Babu, RS | 1 |
| Kordower, JH | 6 |
| Velloso, NA | 1 |
| Dalmolin, GD | 1 |
| Gomes, GM | 1 |
| Rubin, MA | 1 |
| Canas, PM | 1 |
| Cunha, RA | 1 |
| Mello, CF | 1 |
| Xifró, X | 2 |
| Giralt, A | 2 |
| Saavedra, A | 2 |
| García-Martínez, JM | 1 |
| Díaz-Hernández, M | 1 |
| Lucas, JJ | 2 |
| Alberch, J | 6 |
| Pérez-Navarro, E | 6 |
| Maldonado, PD | 2 |
| Molina-Jijón, E | 1 |
| Villeda-Hernández, J | 2 |
| Galván-Arzate, S | 2 |
| Kalonia, H | 5 |
| Nehru, B | 2 |
| Lee, ST | 2 |
| Chu, K | 2 |
| Jung, KH | 1 |
| Im, WS | 1 |
| Park, JE | 2 |
| Lim, HC | 1 |
| Won, CH | 1 |
| Shin, SH | 1 |
| Lee, SK | 1 |
| Kim, M | 2 |
| Roh, JK | 1 |
| Torres, FV | 1 |
| da Silva Filho, M | 1 |
| Antunes, C | 1 |
| Kalinine, E | 1 |
| Antoniolli, E | 1 |
| Portela, LV | 1 |
| Tort, AB | 1 |
| Shemesh, N | 2 |
| Sadan, O | 2 |
| Melamed, E | 2 |
| Offen, D | 2 |
| Cohen, Y | 2 |
| Sanagi, T | 1 |
| Yabe, T | 1 |
| Yamada, H | 1 |
| Vazey, EM | 2 |
| Dottori, M | 1 |
| Jamshidi, P | 1 |
| Tomas, D | 1 |
| Pera, MF | 1 |
| Horne, M | 1 |
| Connor, B | 3 |
| Franěk, M | 1 |
| Vaculín, S | 1 |
| Yamamotová, A | 1 |
| Šťastný, F | 1 |
| Bubeníková-Valešová, V | 1 |
| Rokyta, R | 1 |
| Rekik, L | 1 |
| Daguin-Nerrière, V | 1 |
| Petit, JY | 1 |
| Brachet, P | 2 |
| Kim, SH | 1 |
| Thomas, CA | 1 |
| Cummings, DM | 1 |
| Cepeda, C | 1 |
| Ehrlich, ME | 1 |
| Rué, L | 1 |
| Ortega, Z | 1 |
| Lombroso, PJ | 1 |
| Lin, YT | 1 |
| Chern, Y | 1 |
| Shen, CK | 1 |
| Wen, HL | 1 |
| Chang, YC | 1 |
| Li, H | 1 |
| Cheng, TH | 1 |
| Hsieh-Li, HM | 1 |
| Edalatmanesh, MA | 1 |
| Bahrami, AR | 1 |
| Hosseini, E | 1 |
| Hosseini, M | 1 |
| Khatamsaz, S | 1 |
| Li, Z | 1 |
| Bouckaert, J | 1 |
| Deboeck, F | 1 |
| De Greve, H | 1 |
| Hernalsteens, JP | 1 |
| Colle, D | 1 |
| Hartwig, JM | 1 |
| Soares, FA | 1 |
| Farina, M | 1 |
| Barzilay, R | 1 |
| Dadon-Nahum, M | 1 |
| Blumenfeld-Katzir, T | 1 |
| Assaf, Y | 1 |
| Yeshurun, M | 1 |
| Djaldetti, R | 1 |
| Yamamoto, T | 1 |
| Azechi, H | 1 |
| Board, M | 1 |
| Winkler, C | 2 |
| Klein, A | 1 |
| Lane, EL | 1 |
| Terakata, M | 1 |
| Fukuwatari, T | 1 |
| Sano, M | 1 |
| Nakao, N | 2 |
| Sasaki, R | 1 |
| Fukuoka, S | 1 |
| McLeod, MC | 1 |
| Kobayashi, NR | 1 |
| Sen, A | 1 |
| Baghbaderani, BA | 1 |
| Sadi, D | 1 |
| Ulalia, R | 1 |
| Behie, LA | 1 |
| Mendez, I | 1 |
| Antunes Wilhelm, E | 1 |
| Ricardo Jesse, C | 1 |
| Folharini Bortolatto, C | 1 |
| Wayne Nogueira, C | 1 |
| Zuo, P | 1 |
| Luo, P | 1 |
| Liu, Y | 1 |
| Régulier, E | 1 |
| Pereira de Almeida, L | 1 |
| Sommer, B | 1 |
| Aebischer, P | 3 |
| Déglon, N | 4 |
| Kheramin, S | 1 |
| Body, S | 1 |
| Mobini, S | 1 |
| Ho, MY | 1 |
| Velázquez-Martinez, DN | 1 |
| Bradshaw, CM | 1 |
| Szabadi, E | 1 |
| Deakin, JF | 1 |
| Anderson, IM | 1 |
| Weinelt, S | 1 |
| Peters, S | 1 |
| Bauer, P | 1 |
| Mix, E | 1 |
| Haas, SJ | 1 |
| Dittmann, A | 1 |
| Petrov, S | 1 |
| Wree, A | 1 |
| Cattaneo, E | 3 |
| Knoblich, R | 1 |
| Strauss, U | 1 |
| Rolfs, A | 1 |
| Pawlak, D | 1 |
| Koda, M | 1 |
| Pawlak, S | 1 |
| Wolczynski, S | 1 |
| Buczko, W | 1 |
| Salzberg-Brenhouse, HC | 1 |
| Chen, EY | 3 |
| Baldwin, S | 1 |
| Hogeland, K | 1 |
| Ranelli, S | 1 |
| Lafreniere, D | 1 |
| Perdomo, B | 1 |
| Novak, L | 1 |
| Kladis, T | 1 |
| Fu, K | 1 |
| Basile, AS | 1 |
| Bartus, RT | 1 |
| St'astný, F | 1 |
| Tejkalová, H | 1 |
| Bubeníková, V | 1 |
| Klaschka, J | 1 |
| Formánek, J | 1 |
| Frantík, E | 1 |
| Zuccato, C | 2 |
| Tartari, M | 1 |
| Martorana, A | 3 |
| De March, Z | 2 |
| Ryu, JK | 4 |
| Kim, SU | 3 |
| McLarnon, JG | 4 |
| Joel, D | 4 |
| Ayalon, L | 3 |
| Tarrasch, R | 2 |
| Weiner, I | 3 |
| Diguet, E | 2 |
| Gross, CE | 1 |
| Bezard, E | 1 |
| Tison, F | 4 |
| Doron, R | 1 |
| Hussain, N | 1 |
| Flumerfelt, BA | 1 |
| Rajakumar, N | 1 |
| Sumiyoshi, T | 3 |
| Tsunoda, M | 1 |
| Uehara, T | 3 |
| Tanaka, K | 1 |
| Itoh, H | 2 |
| Sumiyoshi, C | 1 |
| Kurachi, M | 3 |
| Scattoni, ML | 2 |
| Valanzano, A | 2 |
| Reggio, R | 4 |
| McBride, JL | 2 |
| Behrstock, SP | 1 |
| Jakel, RJ | 1 |
| Siegel, I | 1 |
| Svendsen, CN | 1 |
| de Oliveira, DL | 1 |
| Horn, JF | 1 |
| Rodrigues, JM | 1 |
| Frizzo, ME | 1 |
| Moriguchi, E | 1 |
| Wofchuk, S | 1 |
| Tattersfield, AS | 1 |
| Croon, RJ | 1 |
| Liu, YW | 1 |
| Kells, AP | 1 |
| Faull, RL | 4 |
| Olds, ME | 1 |
| Jacques, DB | 1 |
| Kopyov, O | 1 |
| Borlongan, CV | 2 |
| Skinner, SJ | 1 |
| Geaney, M | 1 |
| Vasconcellos, AV | 1 |
| Elliott, RB | 1 |
| Mantoan, L | 1 |
| Egger, KE | 1 |
| Jellinger, KA | 1 |
| Poewe, W | 4 |
| Scherfler, C | 4 |
| Sather, T | 1 |
| Puschban, Z | 5 |
| Bantubungi, K | 2 |
| Jacquard, C | 1 |
| Greco, A | 2 |
| Pintor, A | 2 |
| Chtarto, A | 1 |
| Tai, K | 1 |
| Galas, MC | 1 |
| Tenenbaum, L | 1 |
| Minghetti, L | 2 |
| Brouillet, E | 1 |
| Brotchi, J | 1 |
| Levivier, M | 4 |
| Schiffmann, SN | 1 |
| Blum, D | 2 |
| Rite, I | 1 |
| Machado, A | 1 |
| Cano, J | 1 |
| Venero, JL | 2 |
| Doljansky, J | 1 |
| Schiller, D | 1 |
| Lee, K | 1 |
| Kang, L | 1 |
| Choi, HB | 2 |
| Liang, ZQ | 1 |
| Wang, XX | 1 |
| Wang, Y | 2 |
| Chuang, DM | 2 |
| DiFiglia, M | 2 |
| Chase, TN | 2 |
| Qin, ZH | 2 |
| Samadi, P | 2 |
| Grégoire, L | 2 |
| Izzo, E | 2 |
| Bédard, PJ | 2 |
| Robichon, R | 1 |
| Jaafar, A | 1 |
| Terqui, M | 1 |
| Peschanski, M | 2 |
| Visnyei, K | 1 |
| Tatsukawa, KJ | 2 |
| Erickson, RI | 1 |
| Simonian, S | 1 |
| Oknaian, N | 1 |
| Carmichael, ST | 1 |
| Kornblum, HI | 2 |
| Bari, F | 1 |
| Nagy, K | 1 |
| Busija, DW | 1 |
| Domoki, F | 1 |
| DeMarch, Z | 2 |
| D'Angelo, V | 1 |
| Morello, M | 1 |
| Sancesario, G | 1 |
| Gil, JM | 1 |
| Araújo, IM | 1 |
| Riess, O | 1 |
| Skripuletz, T | 1 |
| von Hörsten, S | 1 |
| Petersén, A | 2 |
| Chen, K | 1 |
| Hughes, SM | 1 |
| Bates, GP | 1 |
| MacDonald, ME | 1 |
| Wheeler, VC | 1 |
| Woodman, B | 1 |
| Ganzella, M | 1 |
| Jardim, FM | 1 |
| Vendite, D | 1 |
| Phillips, W | 1 |
| March, ZD | 1 |
| McLin, JP | 1 |
| Matsuoka, T | 1 |
| Yu, XY | 1 |
| Lin, SG | 1 |
| Chen, X | 1 |
| Zhou, ZW | 1 |
| Liang, J | 1 |
| Duan, W | 1 |
| Chowbay, B | 1 |
| Wen, JY | 1 |
| Chan, E | 1 |
| Cao, J | 1 |
| Li, CG | 1 |
| Zhou, SF | 1 |
| Ramaswamy, S | 1 |
| Aguilera, P | 1 |
| Chánez-Cárdenas, ME | 1 |
| Floriano-Sánchez, E | 1 |
| Barrera, D | 1 |
| Sánchez-González, DJ | 1 |
| Jiménez, PD | 1 |
| Di Paolo, T | 1 |
| Franco, JL | 1 |
| Dafre, AL | 1 |
| Silva-Adaya, D | 1 |
| Herrera-Mundo, MN | 1 |
| Mendoza-Macedo, K | 1 |
| Binienda, Z | 1 |
| Lehrmann, E | 1 |
| Löve, A | 1 |
| Williamson, J | 1 |
| Bari, M | 1 |
| Gasperi, V | 1 |
| De Ceballos, ML | 1 |
| Maccarrone, M | 1 |
| Chen, Q | 1 |
| Harris, C | 1 |
| Brown, CS | 1 |
| Howe, A | 1 |
| Surmeier, DJ | 1 |
| Reiner, A | 1 |
| Nicholson, LF | 2 |
| Waldvogel, HJ | 2 |
| Dragunow, M | 1 |
| Portera-Cailliau, C | 1 |
| Hedreen, JC | 1 |
| Price, DL | 1 |
| Koliatsos, VE | 1 |
| Burns, LH | 1 |
| Pakzaban, P | 1 |
| Deacon, TW | 1 |
| Brownell, AL | 1 |
| Tatter, SB | 1 |
| Jenkins, BG | 1 |
| Isacson, O | 2 |
| Randall, TS | 1 |
| Cahill, DW | 1 |
| Sanberg, PR | 2 |
| Domenici, MR | 2 |
| Sagratella, S | 1 |
| Diana, G | 1 |
| Caporali, MG | 2 |
| Bronzetti, E | 1 |
| Vega, J | 1 |
| Scotti de Carolis, A | 2 |
| Beck, KD | 1 |
| Hefti, F | 1 |
| Silver, RM | 1 |
| Ludwicka, A | 1 |
| Hampton, M | 1 |
| Ohba, T | 1 |
| Bingel, SA | 1 |
| Smith, T | 1 |
| Harley, RA | 1 |
| Maize, J | 1 |
| Schwarz, M | 2 |
| Block, F | 2 |
| Ferrante, RJ | 3 |
| Kowall, NW | 3 |
| Cipolloni, PB | 1 |
| Storey, E | 1 |
| Beal, MF | 3 |
| Schapira, AH | 1 |
| Sei, Y | 1 |
| Paul, IA | 1 |
| Saito, K | 1 |
| Layar, R | 1 |
| Hartley, JW | 1 |
| Morse, HC | 2 |
| Skolnick, P | 1 |
| Anderson, KD | 1 |
| Panayotatos, N | 1 |
| Corcoran, TL | 1 |
| Lindsay, RM | 1 |
| Wiegand, SJ | 1 |
| Robinson, MB | 2 |
| Hopkins, K | 1 |
| Batshaw, ML | 2 |
| McLaughlin, BA | 1 |
| Oster-Granite, ML | 1 |
| Misztal, M | 1 |
| Skangiel-Kramska, J | 1 |
| Niewiadomska, G | 1 |
| Danysz, W | 1 |
| Espey, MG | 1 |
| Tang, Y | 1 |
| Moffett, JR | 1 |
| Namboodiri, MA | 1 |
| Bergqvist, PB | 2 |
| Apelqvist, G | 1 |
| Butterworth, RF | 1 |
| Bengtsson, F | 2 |
| Leroy, EC | 1 |
| Winn, SR | 1 |
| Hantraye, PM | 1 |
| Chu, Y | 1 |
| McDermott, P | 1 |
| Baetge, EE | 1 |
| Reynolds, NC | 1 |
| Lin, W | 1 |
| Meyer Cameron, C | 1 |
| Roerig, DL | 1 |
| Przedborski, S | 1 |
| Veenman, L | 1 |
| Feldon, J | 1 |
| Watts, C | 2 |
| Brasted, PJ | 2 |
| Robbins, TW | 1 |
| Shear, DA | 2 |
| Dong, J | 1 |
| Gundy, CD | 1 |
| Haik-Creguer, KL | 1 |
| Dunbar, GL | 2 |
| Martel, J | 1 |
| Chopin, P | 1 |
| Colpaert, F | 1 |
| Marien, M | 1 |
| Ogura, M | 1 |
| Nakai, K | 1 |
| Itakura, T | 1 |
| Elisabetsky, E | 1 |
| Brum, LF | 1 |
| Lonser, RR | 1 |
| Corthésy, ME | 1 |
| Morrison, PF | 1 |
| Gogate, N | 1 |
| Oldfield, EH | 1 |
| Bordelon, YM | 1 |
| Chesselet, MF | 1 |
| Alexi, T | 1 |
| Hughes, PE | 1 |
| van Roon-Mom, WM | 1 |
| Williams, CE | 1 |
| Clark, RG | 1 |
| Gluckman, PD | 1 |
| Brickell, KL | 1 |
| Henrich-Noack, P | 1 |
| Flor, PJ | 1 |
| Sabelhaus, CF | 1 |
| Prass, K | 1 |
| Dirnagl, U | 1 |
| Gasparini, F | 1 |
| Sauter, A | 1 |
| Rudin, M | 1 |
| Reymann, KG | 1 |
| Tanii, Y | 1 |
| Haik, KL | 1 |
| Schroeder, U | 1 |
| Sabel, BA | 1 |
| Akerud, P | 2 |
| Marco, S | 3 |
| Canals, JM | 2 |
| Tolosa, E | 3 |
| Arenas, E | 4 |
| Donaldson, D | 1 |
| Waldner, R | 1 |
| Seppi, K | 1 |
| Ghorayeb, I | 2 |
| Goebel, GP | 1 |
| Araujo, DM | 1 |
| Cherry, SR | 1 |
| Toyokuni, T | 1 |
| Checa, N | 1 |
| Michels, A | 1 |
| Fernagut, PO | 1 |
| Rouland, R | 1 |
| Canudas, AM | 1 |
| Akerund, P | 1 |
| de Almeida, LP | 2 |
| Zala, D | 1 |
| Wei, H | 1 |
| Senatorov, VV | 1 |
| Wei, W | 1 |
| Qian, Y | 1 |
| Nicholls, T | 1 |
| Nitsos, I | 1 |
| Smythe, G | 1 |
| Walker, DW | 1 |
| Tkác, I | 1 |
| Keene, CD | 1 |
| Pfeuffer, J | 1 |
| Low, WC | 1 |
| Gruetter, R | 1 |
| MacGibbon, GA | 1 |
| Hamilton, LC | 1 |
| Crocker, SF | 1 |
| Costain, WJ | 1 |
| Murphy, KM | 1 |
| Robertson, HA | 1 |
| Denovan-Wright, EM | 1 |
| Roitberg, BZ | 1 |
| Emborg, ME | 1 |
| Sramek, JG | 1 |
| Palfi, S | 1 |
| Bensadoun, JC | 1 |
| Dréano, M | 1 |
| Frank, C | 1 |
| Tebano, MT | 1 |
| Scarchilli, L | 1 |
| Quarta, D | 1 |
| Malchiodi-Albedi, F | 1 |
| Falchi, M | 1 |
| Massotti, M | 1 |
| Hurelbrink, CB | 1 |
| Armstrong, RJ | 1 |
| Oo, TF | 1 |
| Siman, R | 1 |
| Burke, RE | 1 |
| Chase, K | 1 |
| Brundin, P | 1 |
| Aronin, N | 1 |
| Anegawa, NJ | 1 |
| Gorry, E | 1 |
| Djali, S | 1 |
| Mellits, ED | 1 |
| Iacopino, A | 1 |
| Christakos, S | 1 |
| German, D | 1 |
| Sonsalla, PK | 1 |
| Altar, CA | 1 |
| Töpper, R | 1 |
| Sontag, KH | 1 |
| Noth, J | 1 |
| Swartz, KJ | 2 |
| Susel, Z | 1 |
| Engber, TM | 1 |
| Kuo, S | 1 |
| Burton, S | 1 |
| Daya, S | 1 |
| Potgieter, B | 1 |
| Schumacher, JM | 1 |
| Short, MP | 1 |
| Hyman, BT | 1 |
| Breakefield, XO | 1 |
| Yamada, K | 1 |
| Nabeshima, T | 1 |
| Kameyama, T | 1 |
| Zubrycki, EM | 1 |
| Ragozzino, ME | 1 |
| Lu, SY | 1 |
| Norman, AB | 1 |
| Shipley, MT | 1 |
| Moroni, F | 1 |
| Lombardi, G | 1 |
| Carlà, V | 1 |
| Pellegrini, D | 1 |
| Carassale, GL | 1 |
| Cortesini, C | 1 |
| Martin, JB | 1 |
| Ryzhov, IV | 1 |
| Lapin, IP | 1 |
| Goldstein, M | 1 |
| Kuga, S | 1 |
| Kusano, N | 1 |
| Meller, E | 1 |
| Dancis, J | 1 |
| Vezzani, A | 1 |
| Wu, HQ | 1 |
| Tullii, M | 1 |
| Samanin, R | 1 |
| Marx, JL | 1 |
| Davies, SW | 1 |
| Roberts, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| NMDA-Receptor Blockade in Huntington's Chorea[NCT00001930] | Phase 2 | 25 participants | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for quinolinic acid and Disease Models, Animal
| Article | Year |
|---|---|
Cytoskeleton as a Target of Quinolinic Acid Neurotoxicity: Insight from Animal Models.
Topics: Animals; Cytoskeleton; Disease Models, Animal; Intermediate Filaments; Neurons; Neurotoxins; Quinoli | 2018 |
Phytochemical treatments target kynurenine pathway induced oxidative stress.
Topics: Animals; Disease Models, Animal; Glutamic Acid; Humans; Kynurenine; Neurodegenerative Diseases; Neur | 2018 |
Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines.
Topics: Alzheimer Disease; Animals; Central Nervous System; Disease Models, Animal; Energy Metabolism; Gluta | 2018 |
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; Huntington Disease; Kynurenine; Mice; Mutation; P | 2010 |
Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
Topics: Animals; Calcium; Cell Death; Disease Models, Animal; Energy Metabolism; Excitatory Amino Acids; Hum | 2007 |
Animal models of Huntington's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Genetic Vectors; Huntington Disease; Lentiviru | 2007 |
Metabolism and neuropathologic significance of quinolinic acid and kynurenic acid.
Topics: Animals; Disease Models, Animal; HIV Infections; HIV-1; Humans; Kynurenic Acid; Neuritis; Neuroimmun | 1993 |
The use of toxins to elucidate neural function and disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain; Brain Diseases; Disease Models, Animal; Humans; | 1993 |
Quinolinic acid and inflammation.
Topics: Acquired Immunodeficiency Syndrome; Animals; Biomarkers; Brain Ischemia; Disease Models, Animal; HIV | 1993 |
[Endogenous convulsants (review)].
Topics: Amino Acids; Animals; Carbolines; Cats; Cerebral Cortex; Convulsants; Cysteic Acid; Cysteine; Diseas | 1986 |
225 other studies available for quinolinic acid and Disease Models, Animal
| Article | Year |
|---|---|
3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.
Topics: 3-Hydroxyanthranilic Acid; Animals; Apoptosis; Asthma; Cell Line; Disease Models, Animal; Enzyme Act | 2007 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Mast cells and histamine are involved in the neuronal damage observed in a quinolinic acid-induced model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Female; Histamine; Huntington Disease; Mast Cells; Mice; Mice, Inbr | 2022 |
Increased susceptibility to quinolinic acid-induced seizures and long-term changes in brain oscillations in an animal model of glutaric acidemia type I.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Brain; Brain Diseases, Metabolic; Disease Models, Ani | 2022 |
Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies.
Topics: Animals; Antioxidants; Depression; Depressive Disorder, Major; Disease Models, Animal; Humans; Kelch | 2022 |
Bacillus calmette gaurine vaccine ameliorates the neurotoxicity of quinolinic acid in rats via the modulation of antioxidant, inflammatory and apoptotic markers.
Topics: Animals; Antioxidants; BCG Vaccine; Corpus Striatum; Disease Models, Animal; Huntington Disease; Neu | 2023 |
Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioral and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Humans; Huntington Disease; Mice; Neoplasm Gradin | 2020 |
Longitudinal Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging in Sheep (Ovis aries) With Quinolinic Acid Lesions of the Striatum: Time-Dependent Recovery of N-Acetylaspartate and Fractional Anisotropy.
Topics: Animals; Anisotropy; Corpus Striatum; Diffusion Tensor Imaging; Disease Models, Animal; Huntington D | 2020 |
Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Doublecortin Domain Proteins; Doublecortin Protein | 2020 |
Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.
Topics: Aminopyridines; Animals; Benzamides; Brain-Derived Neurotrophic Factor; Cyclic AMP; Cyclic AMP Respo | 2021 |
Non-invasive, neurotoxic surgery reduces seizures in a rat model of temporal lobe epilepsy.
Topics: Animals; Blood-Brain Barrier; Disease Models, Animal; Epilepsy, Temporal Lobe; Intraoperative Neurop | 2021 |
Caenorhabditis elegans as a model for studies on quinolinic acid-induced NMDAR-dependent glutamatergic disorders.
Topics: 1-Octanol; Adenosine Triphosphate; Amino Acid Metabolism, Inborn Errors; Animals; Animals, Genetical | 2021 |
5,6,7 trihydroxy flavone armoured neurodegeneration caused by Quinolinic acid induced huntington's like disease in rat striatum - reinstating the level of brain neurotrophins with special reference to cognitive-socio behaviour, biochemical and histopathol
Topics: Animals; Brain; Cognition; Corpus Striatum; Disease Models, Animal; Flavones; Huntington Disease; Ma | 2022 |
Central Nervous System Infection with Borna Disease Virus Causes Kynurenine Pathway Dysregulation and Neurotoxic Quinolinic Acid Production.
Topics: Animals; Borna Disease; Borna disease virus; Brain; Cell Line; Disease Models, Animal; Gene Expressi | 2017 |
Comparison of the Toxic Effects of Quinolinic Acid and 3-Nitropropionic Acid in C. elegans: Involvement of the SKN-1 Pathway.
Topics: Animals; Antihypertensive Agents; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Corpus St | 2018 |
Regulation of the kynurenine metabolism pathway by Xiaoyao San and the underlying effect in the hippocampus of the depressed rat.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP Resp | 2018 |
Induction of Neuroinflammatory Response and Histopathological Alterations Caused by Quinolinic Acid Administration in the Striatum of Glutaryl-CoA Dehydrogenase Deficient Mice.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Brain Diseases, Metabolic; CD3 Complex; Corpus Striat | 2018 |
The Effect of Tissue Preparation and Donor Age on Striatal Graft Morphology in the Mouse.
Topics: Animals; Brain Tissue Transplantation; Cell Differentiation; Cells, Cultured; Corpus Striatum; Disea | 2018 |
Generating Excitotoxic Lesion Models of Huntington's Disease.
Topics: Animals; Atrophy; Disease Models, Animal; Humans; Huntington Disease; Interneurons; Mice; Microinjec | 2018 |
The rostromedial tegmental nucleus modulates the development of stress-induced helpless behavior.
Topics: Animals; Depression; Disease Models, Animal; Electric Stimulation; Electroshock; Habenula; Helplessn | 2019 |
Comparing the Effects of Ferulic Acid and Sugarcane Aqueous Extract in In Vitro and In Vivo Neurotoxic Models.
Topics: Analysis of Variance; Animals; Animals, Genetically Modified; Birth Rate; Caenorhabditis elegans; Ca | 2018 |
Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Apoptosis; Brain; Coumarins; Disease Models, A | 2018 |
Intraventricular infusion of quinolinic acid impairs spatial learning and memory in young rats: a novel mechanism of lead-induced neurotoxicity.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain; CREB-Binding Protein; Disease Models, Animal | 2018 |
Testing Different Combinations of Acoustic Pressure and Doses of Quinolinic Acid for Induction of Focal Neuron Loss in Mice Using Transcranial Low-Intensity Focused Ultrasound.
Topics: Acoustics; Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Mice; Neu | 2019 |
Longitudinal characterization of cognitive and motor deficits in an excitotoxic lesion model of striatal dysfunction in non-human primates.
Topics: Animals; Cognitive Dysfunction; Corpus Striatum; Disease Models, Animal; Huntington Disease; Longitu | 2019 |
L-dopa response pattern in a rat model of mild striatonigral degeneration.
Topics: Animals; Behavior, Animal; Corpus Striatum; Denervation; Disease Models, Animal; Levodopa; Motor Act | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Protein kinase C is involved in the neuroprotective effect of berberine against intrastriatal injection of quinolinic acid-induced biochemical alteration in mice.
Topics: Animals; Berberine; Cognitive Dysfunction; Disease Models, Animal; Glutamic Acid; Glycogen Synthase | 2019 |
Oxidative stress is related to the deleterious effects of heme oxygenase-1 in an in vivo neuroinflammatory rat model.
Topics: Animals; Apoptosis; Brain; Disease Models, Animal; Ferrous Compounds; Heme Oxygenase-1; Hemin; Iron | 2013 |
Lesions of the dorsomedial striatum impair formation of attentional set in rats.
Topics: Animals; Attention; Behavior, Animal; Corpus Striatum; Discrimination Learning; Disease Models, Anim | 2013 |
Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.
Topics: Aging; Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Huntingti | 2012 |
Why am I lost without dopamine? Effects of 6-OHDA lesion on the encoding of reward and decision process in CA3.
Topics: Action Potentials; Adrenergic Agents; Animals; Brain Injuries; CA3 Region, Hippocampal; Decision Mak | 2013 |
Donor age dependent graft development and recovery in a rat model of Huntington's disease: histological and behavioral analysis.
Topics: Age Factors; Animals; Apomorphine; Brain Tissue Transplantation; Corpus Striatum; Disease Models, An | 2013 |
CaV1.2 calcium channel expression in reactive astrocytes is associated with the formation of amyloid-β plaques in an Alzheimer's disease mouse model.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Astr | 2013 |
The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; H | 2013 |
Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington's disease like symptoms in rats: behavioral, biochemical, cellular and histological evidences.
Topics: Animals; Behavior, Animal; Brain; Caspase 3; Disease Models, Animal; Drug Synergism; Electron Transp | 2013 |
2-Aminonicotinic acid 1-oxides are chemically stable inhibitors of quinolinic acid synthesis in the mammalian brain: a step toward new antiexcitotoxic agents.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Animals; Brain; Cyclic N-Oxides; Disease Models, Animal; Drug | 2013 |
Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.
Topics: Animals; Anti-Infective Agents; Brain; Disease Models, Animal; Drug Combinations; Female; Kynurenic | 2014 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; | 2014 |
Dissociable effects of basolateral amygdala lesions on decision making biases in rats when loss or gain is emphasized.
Topics: Analysis of Variance; Animals; Basolateral Nuclear Complex; Bias; Brain Injuries; Conditioning, Oper | 2014 |
Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition.
Topics: Animals; Brain; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dizocilpine Maleate; | 2014 |
Effects of methylprednisolone and 4-chloro-3-hydroxyanthranilic acid in experimental spinal cord injury in the guinea pig appear to be mediated by different and potentially complementary mechanisms.
Topics: 3-Hydroxyanthranilic Acid; Animals; Behavior, Animal; Disease Models, Animal; Evoked Potentials, Som | 2014 |
Transplantation of induced pluripotent stem cells improves functional recovery in Huntington's disease rat model.
Topics: Animals; Blotting, Western; Cell Differentiation; Cells, Cultured; Corpus Striatum; Disease Models, | 2014 |
Sub-chronic copper pretreatment reduces oxidative damage in an experimental Huntington's disease model.
Topics: Animals; Apomorphine; Copper; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; L | 2014 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Mem | 2014 |
Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease.
Topics: Animals; Antioxidants; Caffeine; Cell Respiration; Corpus Striatum; Disease Models, Animal; Dose-Res | 2014 |
Behavioural profile of Wistar rats with unilateral striatal lesion by quinolinic acid (animal model of Huntington disease) post-injection of apomorphine and exposure to static magnetic field.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agonis | 2015 |
Absence of aryl hydrocarbon receptors increases endogenous kynurenic acid levels and protects mouse brain against excitotoxic insult and oxidative stress.
Topics: Acetyltransferases; Animals; Basic Helix-Loop-Helix Transcription Factors; Brain; Disease Models, An | 2015 |
Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism.
Topics: Animals; Body Weight; Cell Death; Corpus Striatum; Disease Models, Animal; Dose-Response Relationshi | 2015 |
Toxic synergism between quinolinic acid and organic acids accumulating in glutaric acidemia type I and in disorders of propionate metabolism in rat brain synaptosomes: Relevance for metabolic acidemias.
Topics: Amino Acid Metabolism, Inborn Errors; Animals; Brain; Brain Diseases, Metabolic; Disease Models, Ani | 2015 |
True Niacin Deficiency in Quinolinic Acid Phosphoribosyltransferase (QPRT) Knockout Mice.
Topics: Animals; Disease Models, Animal; Mice, Inbred C57BL; Mice, Knockout; Mutation; NAD; Niacin; Nutritio | 2015 |
Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity.
Topics: alpha-Synuclein; Animals; Cell Death; Corpus Striatum; Disease Models, Animal; Gliosis; Humans; Mice | 2015 |
Essential fatty acid-rich diets protect against striatal oxidative damage induced by quinolinic acid in rats.
Topics: Animals; Body Weight; Cholesterol; Corpus Striatum; Disease Models, Animal; Fatty Acids, Essential; | 2017 |
The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Brain; Disease Models, Anima | 2016 |
Female Flinders Sensitive Line rats show estrous cycle-independent depression-like behavior and altered tryptophan metabolism.
Topics: 5-Hydroxytryptophan; Animals; Anxiety; Brain; Depressive Disorder; Disease Models, Animal; Estrous C | 2016 |
Aberrant self-grooming as early marker of motor dysfunction in a rat model of Huntington's disease.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Grooming; Huntingto | 2016 |
Neuroprotective effects of intrastriatal injection of rapamycin in a mouse model of excitotoxicity induced by quinolinic acid.
Topics: Animals; Body Weight; Corpus Striatum; Cytokines; Disease Models, Animal; Dose-Response Relationship | 2017 |
Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamic Acid; Huntington | 2017 |
n-Butylidenephthalide exhibits protection against neurotoxicity through regulation of tryptophan 2, 3 dioxygenase in spinocerebellar ataxia type 3.
Topics: Animals; Ataxin-3; Calcium; Calpain; Cerebellum; Disease Models, Animal; HEK293 Cells; Humans; Macha | 2017 |
Intact intracortical microstimulation (ICMS) representations of rostral and caudal forelimb areas in rats with quinolinic acid lesions of the medial or lateral caudate-putamen in an animal model of Huntington's disease.
Topics: Animals; Brain Mapping; Disease Models, Animal; Electric Stimulation; Forelimb; Huntington Disease; | 2008 |
Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration.
Topics: Animals; Bone Marrow Transplantation; Cerebral Ventricles; Corpus Striatum; Disease Models, Animal; | 2008 |
Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lipid Peroxidation; Male; Meta | 2009 |
Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.
Topics: Animals; Brain; Brain Ischemia; Cells, Cultured; Dendritic Spines; Disease Models, Animal; Disease P | 2009 |
Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Survival; Cerebral Cortex; Corpus Striatum; Cyclic | 2009 |
Ketamine anaesthesia interferes with the quinolinic acid-induced lesion in a rat model of Huntington's disease.
Topics: Anesthetics, Inhalation; Animals; Antiparkinson Agents; Apomorphine; Brain; Disease Models, Animal; | 2009 |
Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake.
Topics: Analysis of Variance; Animals; Atorvastatin; Cell Death; Complex Mixtures; Disease Models, Animal; D | 2009 |
Early nerve ending rescue from oxidative damage and energy failure by L: -carnitine as post-treatment in two neurotoxic models in rat: recovery of antioxidant and reductive capacities.
Topics: Animals; Antioxidants; Brain; Carnitine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2009 |
Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Functional Laterality; Huntingto | 2010 |
Spermine improves recognition memory deficit in a rodent model of Huntington's disease.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory | 2009 |
Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.
Topics: Adult; Aged; Animals; Brain; Brain-Derived Neurotrophic Factor; Calcineurin; Calcineurin Inhibitors; | 2009 |
NAD(P)H oxidase contributes to neurotoxicity in an excitotoxic/prooxidant model of Huntington's disease in rats: protective role of apocynin.
Topics: Acetophenones; Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lipid Peroxidat | 2010 |
Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine.
Topics: Animals; Antioxidants; Brain; Corpus Striatum; Cysteine; Disease Models, Animal; Dyskinesia, Drug-In | 2010 |
Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.
Topics: Animals; Body Weight; Caffeic Acids; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Disease Models, A | 2009 |
Slowed progression in models of Huntington disease by adipose stem cell transplantation.
Topics: Adipocytes; Animals; Cell Line, Tumor; Cells, Cultured; Corpus Striatum; Culture Media, Conditioned; | 2009 |
Electrophysiological effects of guanosine and MK-801 in a quinolinic acid-induced seizure model.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid An | 2010 |
Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels.
Topics: Animals; Aspartic Acid; Behavior, Animal; Brain; Diffusion Magnetic Resonance Imaging; Disease Model | 2010 |
Adenoviral gene delivery of pigment epithelium-derived factor protects striatal neurons from quinolinic acid-induced excitotoxicity.
Topics: Adenoviridae; Amino Acid Sequence; Animals; Biomarkers; Choline O-Acetyltransferase; Corpus Striatum | 2010 |
Comparison of transplant efficiency between spontaneously derived and noggin-primed human embryonic stem cell neural precursors in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Carrier Proteins; Cell Differentiation; Cell Movement; Cell Survival; Disease Models, Anima | 2010 |
Pain perception in neurodevelopmental animal models of schizophrenia.
Topics: Age Factors; Animals; Animals, Newborn; Dipeptides; Disease Models, Animal; Female; Hot Temperature; | 2010 |
Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
Topics: Animals; Antioxidants; Benzhydryl Compounds; Body Weight; Corpus Striatum; Disease Models, Animal; E | 2010 |
Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats.
Topics: Acetates; Analysis of Variance; Animals; Behavior, Animal; Body Weight; Brain; Brain Chemistry; Cata | 2010 |
Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats.
Topics: Analysis of Variance; Animals; Apoptosis; Body Weight; Calcium Channel Blockers; Catalase; Cytokines | 2011 |
Licofelone attenuates quinolinic acid induced Huntington like symptoms: possible behavioral, biochemical and cellular alterations.
Topics: Animals; Behavior, Animal; Biochemical Phenomena; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Dise | 2011 |
γ-Aminobutyric acid type B receptor changes in the rat striatum and substantia nigra following intrastriatal quinolinic acid lesions.
Topics: Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Female; Huntington Disease; Immunohist | 2011 |
Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function.
Topics: Aging; Animals; Corpus Striatum; Disease Models, Animal; Electron Transport Chain Complex Proteins; | 2011 |
Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
Topics: Animals; Brain; Calcineurin; Cell Death; Disease Models, Animal; Gene Expression Regulation; Gene Pr | 2011 |
Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models.
Topics: Animals; Apoptosis; Bone Marrow Transplantation; Caspase 3; Cell Differentiation; Cell Movement; Cel | 2011 |
Neuroprotective effects of mesenchymal stem cell transplantation in animal model of cerebellar degeneration.
Topics: Animals; Cell Count; Cell Survival; Disease Models, Animal; Male; Mesenchymal Stem Cell Transplantat | 2011 |
Nicotinamide dependence of uropathogenic Escherichia coli UTI89 and application of nadB as a neutral insertion site.
Topics: Amino Acid Substitution; Animals; Disease Models, Animal; DNA, Bacterial; Female; Genetic Complement | 2012 |
Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Topics: Animals; Antioxidants; Convulsants; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lip | 2012 |
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.
Topics: Animals; Cell Differentiation; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Humans; Hun | 2012 |
Essential role of excessive tryptophan and its neurometabolites in fatigue.
Topics: Acetylglucosaminidase; Amino Acids, Branched-Chain; Analysis of Variance; Animals; Corpus Striatum; | 2012 |
Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopami | 2012 |
Brain repair in a unilateral rat model of Huntington's disease: new insights into impairment and restoration of forelimb movement patterns.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Fetal Tissue Transplantation; Forelimb; H | 2013 |
Establishment of true niacin deficiency in quinolinic acid phosphoribosyltransferase knockout mice.
Topics: Animals; Body Weight; Disease Models, Animal; Eating; Mice; Mice, Inbred C57BL; Mice, Knockout; NAD; | 2012 |
Transplantation of GABAergic cells derived from bioreactor-expanded human neural precursor cells restores motor and cognitive behavioral deficits in a rodent model of Huntington's disease.
Topics: Animals; Behavior, Animal; Cell Transdifferentiation; Cells, Cultured; Disease Models, Animal; Femal | 2013 |
Correlations between behavioural and oxidative parameters in a rat quinolinic acid model of Huntington's disease: protective effect of melatonin.
Topics: Animals; Behavior, Animal; Catalase; Disease Models, Animal; Huntington Disease; Male; Melatonin; Mo | 2013 |
Cholinergic receptor activity after quinolinic acid caused cerebral injury in rats.
Topics: Alzheimer Disease; Animals; Brain; Choline O-Acetyltransferase; Disease Models, Animal; Learning; Ma | 2002 |
Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Brain; Choline O-Acetyltransferase; Ciliary Neurotrophic Factor; Disease Models, Animal; DN | 2002 |
Effects of quinolinic acid-induced lesions of the orbital prefrontal cortex on inter-temporal choice: a quantitative analysis.
Topics: Animals; Choice Behavior; Conditioning, Operant; Disease Models, Animal; Female; Impulsive Behavior; | 2002 |
Ciliary neurotrophic factor overexpression in neural progenitor cells (ST14A) increases proliferation, metabolic activity, and resistance to stress during differentiation.
Topics: Animals; Apomorphine; Apoptosis; Blotting, Western; Cell Differentiation; Cell Division; Cells, Cult | 2003 |
Contribution of quinolinic acid in the development of anemia in renal insufficiency.
Topics: Anemia; Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Survival; Cobalt; Disease Models, Ani | 2003 |
Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase | 2003 |
[Glutamate receptor dysfunction and psychosis-like behavior in an animal model].
Topics: Animals; Animals, Newborn; Behavior, Animal; Brain; Disease Models, Animal; Quinolinic Acid; Rats; R | 2003 |
Co-localization of brain-derived neurotrophic factor (BDNF) and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain.
Topics: Animals; Blotting, Western; Brain Injuries; Brain-Derived Neurotrophic Factor; Calcium-Binding Prote | 2003 |
Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administrat | 2003 |
Deficits induced by quinolinic acid lesion to the striatum in a position discrimination and reversal task are ameliorated by permanent and temporary lesion to the globus pallidus: a potential novel treatment in a rat model of Huntington's disease.
Topics: Animals; Basal Ganglia; Corpus Striatum; Discrimination Learning; Disease Models, Animal; Female; Gl | 2003 |
Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Clinical Trials as Topic; Corpus | 2004 |
Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus.
Topics: Amphetamine; Animals; Behavior, Animal; Body Weight; Central Nervous System Stimulants; Cognition; D | 2004 |
Glutamatergic regulation of long-term grafts of fetal lateral ganglionic eminence in a rat model of Huntington's disease.
Topics: Animals; Brain Injuries; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dizo | 2004 |
Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Drug Administration Routes; Enzyme Inhibitors; Guanidines; Huntingt | 2004 |
Enhanced locomotor activity in rats with excitotoxic lesions of the entorhinal cortex, a neurodevelopmental animal model of schizophrenia: behavioral and in vivo microdialysis studies.
Topics: Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Dopamine; Dopamine Agents; Entor | 2004 |
Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Huntington Disease; Male; Mo | 2004 |
Human neural stem cell transplants improve motor function in a rat model of Huntington's disease.
Topics: Animals; Astrocytes; Cell Differentiation; Cells, Cultured; Cerebral Cortex; Ciliary Neurotrophic Fa | 2004 |
Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine.
Topics: Administration, Oral; Aging; Animals; Animals, Newborn; Anticonvulsants; Brain; Disease Models, Anim | 2004 |
Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Death; Cell Differentiation; Cell Division; Cell Moveme | 2004 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
Neuroprotection by encapsulated choroid plexus in a rodent model of Huntington's disease.
Topics: Alginates; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain Tis | 2004 |
Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Amino Acid Chloromethyl Ketones; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Cas | 2005 |
Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
Topics: Animals; Biomarkers; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine and cAMP-Regulat | 2005 |
Minocycline in phenotypic models of Huntington's disease.
Topics: Animals; Calpain; Caspases; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Do | 2005 |
Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Corpus Striatum; Cyclopropanes; Denerva | 2005 |
Training specificity, graft development and graft-mediated functional recovery in a rodent model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Count; Corpus Striatum; Disease Models | 2005 |
'Compulsive' lever pressing in rats is enhanced following lesions to the orbital cortex, but not to the basolateral nucleus of the amygdala or to the dorsal medial prefrontal cortex.
Topics: Amygdala; Animals; Behavior, Animal; Compulsive Behavior; Conditioning, Psychological; Disease Model | 2005 |
Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model.
Topics: Animals; Apomorphine; Behavior, Animal; Cell Count; Cells, Cultured; Corpus Striatum; Disease Models | 2005 |
Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Antineoplastic Agents; Carrier Proteins; Caspases; | 2005 |
Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.
Topics: Adult; Aged, 80 and over; Animals; Calbindins; Choline O-Acetyltransferase; Corpus Striatum; Disease | 2005 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose- | 2005 |
Pig xenografts to the immunocompetent rat brain: Survival rates using distinct neurotoxic lesions in the nigrostriatal pathway and two rat strains.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain Tissue Transplantation; Cell Size; Cells, Cultured; Corp | 2005 |
Neural progenitor implantation restores metabolic deficits in the brain following striatal quinolinic acid lesion.
Topics: Analysis of Variance; Animals; Apomorphine; Autoradiography; Behavior, Animal; Cell Count; Corpus St | 2006 |
Kynurenic acid attenuates NMDA-induced pial arteriolar dilation in newborn pigs.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain Ischemia; Cerebral Arteries; Disease Models, | 2006 |
Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Topics: Animals; Calbindin 2; Calbindins; Cell Count; Choline O-Acetyltransferase; Corpus Striatum; Cyclic A | 2006 |
The effects of lateralized training on spontaneous forelimb preference, lesion deficits, and graft-mediated functional recovery after unilateral striatal lesions in rats.
Topics: Animals; Behavior, Animal; Brain Injuries; Brain Tissue Transplantation; Corpus Striatum; Disease Mo | 2006 |
Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.
Topics: Analysis of Variance; Animals; Animals, Genetically Modified; Brain; Disease Models, Animal; Fluores | 2006 |
Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease.
Topics: Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Bromodeoxyuridine; Cell Co | 2006 |
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice.
Topics: Age Factors; Animals; Brain Chemistry; Chromatography, Gas; Chromatography, High Pressure Liquid; Di | 2006 |
Time course of oxidative events in the hippocampus following intracerebroventricular infusion of quinolinic acid in mice.
Topics: AIDS Dementia Complex; Animals; Antioxidants; Cells, Cultured; Disease Models, Animal; Encephalitis; | 2006 |
Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
Topics: Analysis of Variance; Animals; Blotting, Western; Cell Death; Cyclooxygenase 2; Disease Models, Anim | 2006 |
Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease.
Topics: Aging; Animals; Disease Models, Animal; Doublecortin Domain Proteins; Huntington Disease; Immunohist | 2006 |
Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Behavior, Animal; Behavioral Sympt | 2007 |
Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains.
Topics: Animals; Chimera; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Re | 2006 |
Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
Topics: Animals; Cell Survival; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models | 2007 |
Effect of prefrontal cortex inactivation on behavioral and neurochemical abnormalities in rats with excitotoxic lesions of the entorhinal cortex.
Topics: Amygdala; Anesthetics, Local; Animals; Denervation; Disease Models, Animal; Dopamine; Dopamine Uptak | 2007 |
Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration.
Topics: Adenosine A2 Receptor Antagonists; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cycl | 2007 |
Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
Topics: Alzheimer Disease; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tran | 2007 |
Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease.
Topics: Animals; Basal Ganglia; Calcium; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Hu | 2007 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskines | 2008 |
Evaluation of glutathione metabolism in NMDA preconditioning against quinolinic acid-induced seizures in mice cerebral cortex and hippocampus.
Topics: Analysis of Variance; Animals; Cerebral Cortex; Disease Models, Animal; Drug Interactions; Excitator | 2007 |
Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.
Topics: Animals; Antioxidants; Brain; Carnitine; Convulsants; Disease Models, Animal; Dose-Response Relation | 2008 |
Glial activation precedes seizures and hippocampal neurodegeneration in measles virus-infected mice.
Topics: Animals; Animals, Newborn; Astrocytes; Behavior, Animal; Cell Count; Coloring Agents; Cricetinae; Di | 2008 |
Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Communication; Cell Survival; Cerebral Cortex; Corp | 2008 |
Glutamate-mediated excitotoxic death of cultured striatal neurons is mediated by non-NMDA receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Basal Ganglia; Cell Death; Cells, | 1995 |
GABA and GABAA receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease.
Topics: Animals; Autoradiography; Disease Models, Animal; Flunitrazepam; Gene Expression; Huntington Disease | 1995 |
Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Corpus Striatum; Disease Models, Animal; DNA; DN | 1995 |
Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Huntington Disease; Macaca mulat | 1995 |
Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Functional Laterali | 1995 |
Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease in rats.
Topics: Animals; Behavior, Animal; Body Weight; Disease Models, Animal; Electric Stimulation; Electroencepha | 1994 |
Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Animal; Enzyme Induction; Fem | 1994 |
CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease.
Topics: Adenosine; Amphetamine; Animals; Disease Models, Animal; Huntington Disease; Male; Motor Activity; P | 1994 |
A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
Topics: Animals; Disease Models, Animal; Eosinophilia-Myalgia Syndrome; Fascia; Female; Mice; Mice, Inbred C | 1994 |
Visual evoked potentials in the rat quinolinic acid model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Evoked Potentials, Visual; Huntington Disease; Inj | 1993 |
Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
Topics: Animals; Brain; Caudate Nucleus; Disease Models, Animal; Histocytochemistry; Huntington Disease; Imm | 1993 |
Quinolinic acid levels in a murine retrovirus-induced immunodeficiency syndrome.
Topics: AIDS Dementia Complex; Animals; Brain Chemistry; Cytokines; Defective Viruses; Disease Models, Anima | 1996 |
Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Death; Ciliary Neurotrophic Factor; Corpus Striatum | 1996 |
Evidence of excitotoxicity in the brain of the ornithine carbamoyltransferase deficient sparse fur mouse.
Topics: Ammonia; Animals; Brain Damage, Chronic; Disease Models, Animal; Glutamine; Hair; Metabolism, Inborn | 1995 |
Subchronic intraventricular infusion of quinolinic acid produces working memory impairment--a model of progressive excitotoxicity.
Topics: Alzheimer Disease; Animals; Cerebral Ventricles; Disease Models, Animal; Disease Progression; Drug A | 1996 |
Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis.
Topics: AIDS Dementia Complex; Animals; Brain Chemistry; Dendritic Cells; Disease Models, Animal; Female; Li | 1996 |
Brain extracellular quinolinic acid in chronic experimental hepatic encephalopathy as assessed by in vivo microdialysis: acute effects of L-tryptophan.
Topics: Animals; Brain; Disease Models, Animal; Hepatic Encephalopathy; Male; Microdialysis; Quinolinic Acid | 1996 |
Is quinolinic acid involved in the pathogenesis of hepatic encephalopathy?
Topics: Animals; Brain; Cerebral Cortex; Disease Models, Animal; Extracellular Space; Hepatic Encephalopathy | 1996 |
Quinolinic acid accumulation in injured spinal cord: time course, distribution, and species differences between rat and guinea pig.
Topics: Animals; Disease Models, Animal; Female; Guinea Pigs; Quinolinic Acid; Rats; Rats, Sprague-Dawley; S | 1997 |
Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
Topics: Animals; Brain; Cell Line; Ciliary Neurotrophic Factor; Corpus Striatum; Cricetinae; Disease Models, | 1997 |
Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Excitatory Amino Acid Agonists; | 1997 |
Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment.
Topics: Animals; Autoradiography; Benzazepines; Binding, Competitive; Cholinergic Agents; Corpus Striatum; D | 1998 |
Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electrolysis; Globus Pallidus; Huntington Disease; | 1998 |
Effects of severity of host striatal damage on the morphological development of intrastriatal transplants in a rodent model of Huntington's disease: implications for timing of surgical intervention.
Topics: Acetylcholinesterase; Animals; Atrophy; Cell Count; Cell Survival; Cell Transplantation; Corpus Stri | 1998 |
Striatal lesions produce distinctive impairments in reaction time performance in two different operant chambers.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Excitatory Amino Aci | 1998 |
Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
Topics: Animals; Cerebral Ventricles; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV | 1998 |
Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum.
Topics: Adrenergic alpha-Antagonists; Animals; Apomorphine; Behavior, Animal; Benzofurans; Choline O-Acetylt | 1998 |
Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Brain Tissue Transp | 1999 |
Anticonvulsant properties of linalool in glutamate-related seizure models.
Topics: Acyclic Monoterpenes; Animals; Anticonvulsants; Cerebral Cortex; Disease Models, Animal; Dizocilpine | 1999 |
The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Electroencephalography; Frontal Lobe; Huntington D | 1999 |
Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Albumins; Animals; Antiparkinson Agents; Disease Model | 1999 |
Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia.
Topics: Animals; Basal Ganglia; Corpus Striatum; Cytoskeleton; Disease Models, Animal; DNA Damage; Efferent | 1999 |
The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Topics: Animals; Calbindin 2; Calbindins; Cell Count; Choline O-Acetyltransferase; Cholinergic Fibers; Corpu | 1999 |
Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes.
Topics: Animals; Autoradiography; Corpus Striatum; Disease Models, Animal; Huntington Disease; Immunohistoch | 1999 |
Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage.
Topics: Action Potentials; Animals; Brain Diseases; Brain Ischemia; Cell Hypoxia; Corpus Striatum; Cytoprote | 2000 |
Neonatal lesions of the left entorhinal cortex affect dopamine metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Animals, Newborn; Brain; Caudate Nucleus; Disease | 2000 |
Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease.
Topics: Acetylcholinesterase; Animals; Brain Tissue Transplantation; Cell Count; Cell Differentiation; Cell | 2000 |
Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Implants, Experimental; Male; | 2000 |
Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.
Topics: Animals; Calbindins; Cell Count; Choline O-Acetyltransferase; Corpus Striatum; Disease Models, Anima | 2000 |
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin | 2000 |
Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Animals; Apomorphine; Autoradiography; Binding, Competitive; Brain Tissue Transplantation; Corpus St | 2000 |
Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy).
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glial Fibrillary Acidic Protein; Male; Motor Activ | 2000 |
Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.
Topics: Animals; Autoradiography; Benzazepines; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine A | 2000 |
Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area.
Topics: 3T3 Cells; Animals; Axonal Transport; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Colchicine | 2001 |
Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
Topics: Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Forelimb; Male; Micr | 2001 |
Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Death; Cell Line; Cell Transplantation; Corpus Stri | 2000 |
Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease.
Topics: Animals; beta-Galactosidase; Ciliary Neurotrophic Factor; Cytomegalovirus; Disease Models, Animal; F | 2001 |
Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease.
Topics: Animals; Antimanic Agents; Benzazepines; Cell Death; Cyclin D1; Disease Models, Animal; Dopamine Ant | 2001 |
Kynurenine production and catabolism in fetal sheep with embolized or nonembolized placentas.
Topics: Animals; Disease Models, Animal; Embolism; Female; Fetal Blood; Fetal Diseases; Fetal Growth Retarda | 2001 |
Metabolic changes in quinolinic acid-lesioned rat striatum detected non-invasively by in vivo (1)H NMR spectroscopy.
Topics: Amino Acids; Animals; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Energy M | 2001 |
Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington's disease transgenic mice.
Topics: Animals; Anti-Dyskinesia Agents; Central Nervous System Stimulants; Corpus Callosum; Corpus Striatum | 2002 |
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
Topics: Animals; Brain Mapping; Caudate Nucleus; Cebus; Disease Models, Animal; Frontal Lobe; Humans; Huntin | 2002 |
Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.
Topics: Acetylcholine; Animals; Disease Models, Animal; Female; gamma-Aminobutyric Acid; Genetic Vectors; Hu | 2001 |
Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.
Topics: Animals; Behavior, Animal; Calcium; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dose-R | 2002 |
Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Disease Models, Animal; Enkephalins; Globus Pallidus; Gluta | 2002 |
Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS.
Topics: Animals; Brain Tissue Transplantation; Cell Differentiation; Cell Movement; Disease Models, Animal; | 2002 |
Distinct nuclear and cytoplasmic localization of caspase cleavage products in two models of induced apoptotic death in dopamine neurons of the substantia nigra.
Topics: Actins; Animals; Antibody Specificity; Apoptosis; Caspases; Cell Compartmentation; Cell Nucleus; Cyt | 2002 |
Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; He | 2002 |
Quinolinate in brain and cerebrospinal fluid in rat models of congenital hyperammonemia.
Topics: Acetates; Ammonia; Animals; Brain; Disease Models, Animal; Hydroxyindoleacetic Acid; Male; Metabolis | 1992 |
Calbindin-D28K-containing neurons in animal models of neurodegeneration: possible protection from excitotoxicity.
Topics: Animals; Basal Ganglia Diseases; Biogenic Amines; Calbindin 1; Calbindins; Calcium; Cell Survival; D | 1992 |
Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Evoked Potentials, Somatosensory; Huntington Disea | 1992 |
Chronic quinolinic acid lesions in rats closely resemble Huntington's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Atrophy; Biogenic Amines; Cerebra | 1991 |
Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease.
Topics: Animals; Choline O-Acetyltransferase; Convulsants; Corpus Striatum; Disease Models, Animal; Glutamat | 1991 |
Melatonin modulates apomorphine-induced rotational behaviour.
Topics: Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Hun | 1991 |
Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids.
Topics: Animals; Cell Line; Corpus Striatum; Disease Models, Animal; Fibroblasts; Genetic Engineering; Hunti | 1991 |
Impairment of active avoidance response in rats with continuous infusion of quinolinic acid into the lateral ventricle.
Topics: Animals; Avoidance Learning; Behavior, Animal; Convulsants; Disease Models, Animal; Injections, Intr | 1991 |
NADPH-diaphorase-containing neurons and cytochrome oxidase activity following striatal quinolinic acid lesions and fetal striatal transplants.
Topics: Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Electron Transport C | 1990 |
Content of quinolinic acid and of other tryptophan metabolites increases in brain regions of rats used as experimental models of hepatic encephalopathy.
Topics: Acetates; Animals; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Disease Models, Animal; Hepatic E | 1986 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |
Dopamine agonist induced self-mutilative biting behavior in monkeys with unilateral ventromedial tegmental lesions of the brainstem: possible pharmacological model for Lesch-Nyhan syndrome.
Topics: Animals; Brain Diseases; Cercopithecus; Chlorocebus aethiops; Corpus Striatum; Disease Models, Anima | 1986 |
Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Chlorpromazine; Diazepam; Disease Models, | 1986 |
Animals yield clues to Huntington's disease.
Topics: Animals; Brain; Disease Models, Animal; Humans; Huntington Disease; Neurons; Quinolinic Acid; Quinol | 1987 |
Model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Huntington Disease; Quinolinic Acid; Quinolinic Acids | 1988 |